Samsung Biologics, a global contract development and manufacturing organization (CDMO), has announced a series of manufacturing deals with a Europe-based pharmaceutical company.
 
The disclosed deals, worth over $668 million combined, will run through December 2031. The latest agreements bring up the company’s cumulative contract value for this year to more than $4 billion.
 
“We are delighted to expand our partnership with the European pharmaceutical company toward our shared commitment to delivering high-quality biopharmaceuticals to patients,” said John Rim, President and CEO of Samsung Biologics. “As we further expand strategic collaboration with clients worldwide, we also make continued investments in our capabilities and manufacturing technologies. Our goal is to provide the highest-quality services at every stage and deepen our trusted partnerships.”
 
The company has secured several significant deals this year, solidifying its customer base across the U.S., Asia, and Europe. It now claims to be partnered with 17 of the world’s top 20 pharmaceutical companies.